Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Cardinal’s SEC request

Executive Summary

Wholesaler receives an SEC request for "historical financial and related information," including information on the accounting treatment of a $22 mil. settlement in vitamin price-fixing litigation. Cardinal describes the request as part of an "informal inquiry" and says it is "highly confident in its accounting and financial disclosure practices, and intends to cooperate fully." Questions about the timing of Cardinal's recognition of the settlement funds were raised in April by the Wall Street Journal (1"The Pink Sheet" April 14, 2003, p. 28)...

You may also be interested in...



Cardinal Revenue Classification Is Subject Of SEC/U.S. Attorney Investigation

Cardinal's revenue classification practices are the subject of an investigation by the Securities & Exchange Commission and the New York U.S. Attorney

Cardinal under formal SEC investigation

Securities & Exchange Commission initiates formal investigation into Cardinal's historical financial information relating in part to the accounting treatment of $22 mil. in revenues received from a vitamin price-fixing litigation settlement. SEC has been investigating the issue informally since October (1"The Pink Sheet" Oct. 13, 2003, In Brief). In April, Cardinal's audit committee retained independent counsel to conduct an internal review...

Iraq War Rally Helps Rx Stocks; Investors Adjust To Diminished Expectations?

Pfizer's steady progress toward closing the Pharmacia acquisition is giving the company a winning profile on Wall Street against the backdrop of a broader market rally fueled by the U.S. war in Iraq

Latest Headlines
See All
UsernamePublicRestriction

Register

PS042599

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel